Phocas Financial Corp. Sells 57,895 Shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC)

Phocas Financial Corp. lessened its stake in Acadia Healthcare Company, Inc. (NASDAQ:ACHC) by 80.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 14,330 shares of the company’s stock after selling 57,895 shares during the period. Phocas Financial Corp.’s holdings in Acadia Healthcare were worth $568,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Blue Trust Inc. increased its position in shares of Acadia Healthcare by 69.4% during the fourth quarter. Blue Trust Inc. now owns 842 shares of the company’s stock worth $33,000 after buying an additional 345 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Acadia Healthcare by 40.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,040 shares of the company’s stock worth $41,000 after acquiring an additional 301 shares in the last quarter. Fifth Third Bancorp lifted its stake in shares of Acadia Healthcare by 56.0% in the 4th quarter. Fifth Third Bancorp now owns 1,264 shares of the company’s stock valued at $50,000 after purchasing an additional 454 shares during the period. Covestor Ltd boosted its position in shares of Acadia Healthcare by 834.4% during the 3rd quarter. Covestor Ltd now owns 1,140 shares of the company’s stock valued at $72,000 after purchasing an additional 1,018 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new stake in Acadia Healthcare during the third quarter worth approximately $86,000.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ACHC. StockNews.com cut Acadia Healthcare from a “hold” rating to a “sell” rating in a report on Monday, January 6th. KeyCorp upgraded Acadia Healthcare from a “sector weight” rating to an “overweight” rating and set a $70.00 price target on the stock in a report on Tuesday, January 7th. TD Cowen decreased their price objective on Acadia Healthcare from $70.00 to $66.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $52.00 target price on shares of Acadia Healthcare in a report on Tuesday, December 10th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Acadia Healthcare from a “hold” rating to a “buy” rating and upped their price objective for the stock from $45.00 to $75.00 in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $70.22.

Acadia Healthcare Stock Up 4.1 %

Acadia Healthcare stock opened at $42.35 on Wednesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.07 and a current ratio of 1.07. The stock has a market cap of $3.93 billion, a PE ratio of 13.89, a price-to-earnings-growth ratio of 1.46 and a beta of 1.30. The firm’s 50-day simple moving average is $42.18 and its 200 day simple moving average is $52.38. Acadia Healthcare Company, Inc. has a fifty-two week low of $36.50 and a fifty-two week high of $87.77.

Acadia Healthcare Profile

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.